Nuplazid Approved for Parkinson's Hallucinations

MONDAY, May 2, 2016 — Nuplazid (pimavanserin) has been approved by the U.S. Food and Drug Administration to treat hallucinations and delusions associated with Parkinson’s disease.
As many as half of people with Parkinson’s may have psychosis that…
Source: Topamax